T-bet and eomesodermin are required for T cell-mediated antitumor immune responses

Journal of Immunology

Volumn 185, Issue 6, 2010, Pages 3174-3183

  Zhu, Yibei ^a,b   Ju, Songguang ^a   Chen, Elizabeth ^c   Dai, Shao ^a   Li, Changyou ^a   Morel, Penelope ^a   Liu, Lin ^a   Zhang, Xueguang ^b   Lu, Binfeng ^a,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SOOCHOW UNIVERSITY   (China)

^c CARNEGIE MELLON UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOMESODERMIN; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 17;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CANCER MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL INFILTRATION; CELLULAR IMMUNITY; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE DELETION; GERM LINE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, CD44; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; DISEASE MODELS, ANIMAL; LYMPHOCYTES, TUMOR-INFILTRATING; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; T-BOX DOMAIN PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78649853665     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000749     Document Type: Article

References (35)

1. Karin, M. 2006. Nuclear factor-κB in cancer development and progression. Nature 441: 431-436. (Pubitemid 44050137)
2. Girardi, M., D. E. Oppenheim, C. R. Steele, J. M. Lewis, E. Glusac, R. Filler, P. Hobby, B. Sutton, R. E. Tigelaar, and A. C. Hayday. 2001. Regulation of cutaneous malignancy by γδ T cells. Science 294: 605-609.
3. Finn, O. J. 2003. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3: 630-641.
4. Dunn, G. P., C. M. Koebel, and R. D. Schreiber. 2006. Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol. 6: 836-848.
5. Vesalainen, S., P. Lipponen, M. Talja, and K. Syrjänen. 1994. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 30A: 1797-1803.
6. + T cell infiltrations within esophageal carcinomas. Cancer Res. 61: 3932-3936.
7. Galon, J., A. Costes, F. Sanchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind, et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
8. Dieu-Nosjean, M. C., M. Antoine, C. Danel, D. Heudes, M. Wislez, V. Poulot, N. Rabbe, L. Laurans, E. Tartour, L. de Chaisemartin, et al. 2008. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26: 4410-4417.
9. + T cell function by the transcription factor Eomesodermin. Science 302: 1041-1043.
10. Peng, S. L., M. J. Townsend, J. L. Hecht, I. A. White, and L. H. Glimcher. 2004. T-bet regulates metastasis rate in a murine model of primary prostate cancer. Cancer Res. 64: 452-455.
11. Werneck, M. B., G. Lugo-Villarino, E. S. Hwang, H. Cantor, and L. H. Glimcher. 2008. T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J. Immunol. 180: 8004-8010.
12. Liu, P., N. A. Jenkins, and N. G. Copeland. 2003. A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13: 476-484.
13. + T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6: 1236-1244.
14. + T cell differentiation. J. Immunol. 177: 7515-7519.
15. + T cells lacking T-bet and eomesodermin. Science 321: 408-411.
16. Cruz-Guilloty, F., M. E. Pipkin, I. M. Djuretic, D. Levanon, J. Lotem, M. G. Lichtenheld, Y. Groner, and A. Rao. 2009. Runx3 and T-box proteins cooperate to establish the transcriptional program of effector CTLs. J. Exp. Med. 206: 51-59.
17. Szabo, S. J., B. M. Sullivan, C. Stemmann, A. R. Satoskar, B. P. Sleckman, and L. H. Glimcher. 2002. Distinct effects of T-bet in TH1 lineage commitment and IFN-γ production in CD4 and CD8 T cells. Science 295: 338-342.
18. Liu, S. J., J. P. Tsai, C. R. Shen, Y. P. Sher, C. L. Hsieh, Y. C. Yeh, A. H. Chou, S. R. Chang, K. N. Hsiao, F. W. Yu, and H. W. Chen. 2007. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6. J. Leukoc. Biol. 82: 354-360.
19. Pagès, F., A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik, A. Kirilovsky, M. Nilsson, D. Damotte, et al. 2005. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353: 2654-2666.
20. Atreya, I., C. C. Schimanski, C. Becker, S. Wirtz, H. Dornhoff, E. Schnürer, M. R. Berger, P. R. Galle, W. Herr, and M. F. Neurath. 2007. The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut 56: 1572-1578.
21. Schreiber, K., D. A. Rowley, G. Riethmüller, and H. Schreiber. 2006. Cancer immunotherapy and preclinical studies: why we are not wasting our time with animal experiments. Hematol. Oncol. Clin. North Am. 20: 567-584.
22. + T-cell trafficking. Blood 106: 3432-3439.
23. Wang, J., J. W. Fathman, G. Lugo-Villarino, L. Scimone, U. von Andrian, D. M. Dorfman, and L. H. Glimcher. 2006. Transcription factor T-bet regulates inflammatory arthritis through its function in dendritic cells. J. Clin. Invest. 116: 414-421.
24. Glimcher, L. H. 2007. Trawling for treasure: tales of T-bet. Nat. Immunol. 8: 448-450.
25. Garrett, W. S., S. Punit, C. A. Gallini, M. Michaud, D. Zhang, K. S. Sigrist, G. M. Lord, J. N. Glickman, and L. H. Glimcher. 2009. Colitis-associated colorectal cancer driven by T-bet deficiency in dendritic cells. Cancer Cell 16: 208-219.
26. Weinreich, M. A., K. Takada, C. Skon, S. L. Reiner, S. C. Jameson, and K. A. Hogquist. 2009. KLF2 transcription-factor deficiency in T cells results in unrestrained cytokine production and upregulation of bystander chemokine receptors. Immunity 31: 122-130.
27. Beima, K. M., M. M. Miazgowicz, M. D. Lewis, P. S. Yan, T. H. Huang, and A. S. Weinmann. 2006. T-bet binding to newly identified target gene promoters is cell type-independent but results in variable context-dependent functional effects. J. Biol. Chem. 281: 11992-12000.
28. Li, M. O., S. Sanjabi, and R. A. Flavell. 2006. Transforming growth factor-β controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 25: 455-471.
29. Mrass, P., I. Kinjyo, L. G. Ng, S. L. Reiner, E. Puré, and W. Weninger. 2008. CD44 mediates successful interstitial navigation by killer T cells and enables efficient antitumor immunity. Immunity 29: 971-985.
30. Stoicov, C., X. Fan, J. H. Liu, G. Bowen, M. Whary, E. Kurt-Jones, and J. Houghton. 2009. T-bet knockout prevents Helicobacter felis-induced gastric cancer. J. Immunol. 183: 642-649.
31. Neurath, M. F., B. Weigmann, S. Finotto, J. Glickman, E. Nieuwenhuis, H. Iijima, A. Mizoguchi, E. Mizoguchi, J. Mudter, P. R. Galle, et al. 2002. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195: 1129-1143.
32. + T cells for adoptive immunotherapy. Blood 111: 5326-5333.
33. Djuretic, I. M., D. Levanon, V. Negreanu, Y. Groner, A. Rao, and K. M. Ansel. 2007. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat. Immunol. 8: 145-153.
34. + T cells. J. Exp. Med. 204: 2015-2021.
35. + T cell fates via the graded expression of T-bet transcription factor. Immunity 27: 281-295.